R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron
- PMID: 2828537
R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron
Abstract
(-)Deprenyl, when administered continuously in small doses (0.25 mg/kg/day), facilitates the activity of the nigrostriatal dopaminergic neuron because of its highly characteristic complex spectrum of pharmacologic activity: it is a highly potent and selective inhibitor of B-type MAO; it inhibits the reuptake of dopamine; it inhibits dopamine autoreceptors; it enhances scavenger function. 1) (-)Deprenyl treatment decreased significantly the activity of the cholinergic interneurons. In a series of experiments the acetylcholine (ACh) content was found to be 0.69 nmole/mg protein in the striatum of untreated rats, whereas a significantly higher amount of ACh (0.86 nmol/mg protein) was found in the rat striatum after two week pretreatment with (-)deprenyl, and the fractional rate constant (kb) of ACh efflux from the cholinergic interneurons of the striatum decreased significantly in the (-)deprenyl-treated group from 9.1 +/- 0.8 to 6.2 +/- 0.55. 2) The (-)deprenyl-induced increase of the dopaminergic tone in the striatum was proved by measurements of the activity of the nigrostriatal dopaminergic neuron. Whereas the striatum of untreated rats contained 52.7 +/- 1.6 nmole/g dopamine (DA) and the turnover rate (TRDA) was found to be 13.7 +/- 1.3 nmole/g/hr, the striatum of rats pretreated with 0.25 mg/kg (-)deprenyl daily for 28 days contained significantly higher amount of DA (81.77 +/- 5.7 nmole) and the turnover rate increased significantly to 24.44 +/- 1.1. Using the Glowinski-Iversen preparation we found that from the striata of untreated rats 200.0 +/- 25.8 pmole/g/min DA was released to KCl stimulation, whereas the amount of DA released to stimulation from the striata of rats pretreated with (-)deprenyl for 3 weeks increased significantly to 1452.2 +/- 183.1 pmole/g/min. 3) (-)Deprenyl inhibits the uptake of dopamine into the nigrostriatal dopaminergic neuron. In a new series of experiments we found that 420 +/- 21 pmole/g protein 3H-DA was taken up within 5 minutes in the striatum slices of untreated rats. Pretreatment of the rats with 0.25 mg/kg (-)deprenyl daily for two weeks decreased significantly the uptake of DA to 284 +/- 28 pmole/mg. 4) In a new series of experiments we found that the striata of untreated rats emitted 404.2 +/- 36.2 pmole/g/min ACh to ouabain stimulation but the striata dissected from rats pretreated with 6-hydroxy-dopamine (6-OHDA) released 811.4 +/- 49.2 pmol/g/min (p less than or equal to 0.001).
Similar articles
-
[Medicamentous strategy for improving the quality of life in the senescence].Wien Med Wochenschr Suppl. 1986;98:1-18. Wien Med Wochenschr Suppl. 1986. PMID: 3097965 German.
-
Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.J Pharmacol Exp Ther. 1991 Sep;258(3):1019-26. J Pharmacol Exp Ther. 1991. PMID: 1679846
-
[History of deprenyl--the first selective inhibitor of monoamine oxidase type B].Vopr Med Khim. 1997 Nov-Dec;43(6):482-93. Vopr Med Khim. 1997. PMID: 9503565 Review. Russian.
-
Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.J Pharmacol Exp Ther. 1991 Nov;259(2):841-7. J Pharmacol Exp Ther. 1991. PMID: 1658311
-
The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.J Neural Transm Suppl. 1993;40:69-91. J Neural Transm Suppl. 1993. PMID: 8294902 Review.
Cited by
-
Restoration and putative protection in Parkinsonism.Neurotox Res. 2000;2(2-3):251-92. doi: 10.1007/BF03033798. Neurotox Res. 2000. PMID: 16787845
-
Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.Clin Pharmacokinet. 1997 Aug;33(2):91-102. doi: 10.2165/00003088-199733020-00002. Clin Pharmacokinet. 1997. PMID: 9260033 Review.
-
Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.J Neural Transm Gen Sect. 1995;102(1):19-34. doi: 10.1007/BF01276562. J Neural Transm Gen Sect. 1995. PMID: 8785021
-
Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson's Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance.Front Neurol. 2017 Oct 24;8:542. doi: 10.3389/fneur.2017.00542. eCollection 2017. Front Neurol. 2017. PMID: 29114238 Free PMC article.
-
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).Mol Psychiatry. 2016 Nov;21(11):1499-1503. doi: 10.1038/mp.2016.127. Epub 2016 Aug 2. Mol Psychiatry. 2016. PMID: 27480491 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources